KING OF PRUSSIA, Pa., Sept. 4, 2014 (GLOBE NEWSWIRE) -- Emergent Health Corp. (Pink Sheets:EMGE) (the "Company") announced in May 2014 it was in the process of placing a controlling interest to a shareholder group including Clover Capital Corp. and Parcae Capital Corp. The Company is pleased to announce that this control group now includes several other key people and the transaction was completed August 26, 2014. The Company accepted the resignation of all current Board of Directors (BOD). New (BOD) and officer appointments will be announced by the Company at a future date. Other plans are a Form 10 filing to become an SEC fully reporting Company and an S-1 filing for a capital raise.
The Company is pleased to announce that this control group now includes several key people and the transaction was completed August 26, 2014. The Company accepted the resignation of all current Board of Directors (BOD). New (BOD) and officer appointments will be announced by the Company at a future date. Other plans are a Form 10 filing to become an SEC fully reporting Company and an S-1 filing for a capital raise.
Stephen A Hussey, M.B.A. is a lead investor and is now Chief Executive Officer of the Company. Mr. Hussey was a senior sales and marketing executive for Merck & Co. (MRK) specializing in all phases of Pharmaceutical and Medical Education, Sales, Marketing and Business Development and Brand-based Initiatives to health care professionals, to both media and retail outlets, and to top executive industry colleagues over the last 28 years. He plans to investigate the wellness products of the Company that will address unmet medical and personal health needs. As Vice President of Business Development at Comprehensive Medical Communications, Inc. (CMC), in Germantown, Maryland, Mr. Hussey was directly responsible for academic and professional strategic planning, new client development, sales, customer relations, management development and implementation of CME projects for key pharmaceutical clients (i.e. Merck, Novartis (NVS), Eli Lilly and Company (LLY), Teva Pharmaceuticals, Inc. (TEVA), and E. I. du Pont de Nemours and Company (DD) to name a few.
Mr. Hussey stated, "I am very excited about this unique opportunity. The Company has an extensive patent portfolio focused on the emerging field of Stem Cell Nutrition." Hussey further commented, "We anticipate filing an Investigational New Drug Application (INDs) with the FDA for our patented Nutracan™ product for compassionate use for wasting associated with HIV/AIDs and nutritional support in Oncology."
John R. Launie, Jr., CPA , M.B.A. has been appointed Chief Financial Officer and Treasurer. Mr. Launie began his career with Arthur Andersen & Co. in 1976 after earning his Undergraduate Degree in Economics from Boston College and Master Degree in Accounting/MBA from Northeastern University. After serving as a Senior Accountant for three years, John moved to Ernst & Young where he ascended to the level of Senior Manager in the Audit Division. John's audit expertise extended to includes clients such as; State Street Bank, Arthur D. Little, American Biltrite and Lechmere Sales (a Division of Dayton-Hudson Corporation), all of which were public companies. With such a wealth of experience, strong centers of influence and diverse background Mr. Launie is expected to bring ongoing stability for the Company. The Company believes this new team, along with its proof of concept, is the foundation for dynamic growth.
This press release contains certain "forward-looking" statements, defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are estimates reflecting the company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the company.This press release is provided for information purposes only and is not intended to constitute an offer to sell or a solicitation of an offer to buy securities.
CONTACT: Emergent Health Corp. 484-518-9000Source:Emergent Health Corp.